|1.||Borowicz, K K: 3 articles (10/2004 - 06/2000)|
|2.||Czuczwar, S J: 3 articles (10/2004 - 06/2000)|
|3.||Czuczwar, Stanisław J: 3 articles (01/2004 - 08/2002)|
|4.||Grossman, Stuart A: 2 articles (04/2010 - 09/2009)|
|5.||Desideri, Serena: 2 articles (04/2010 - 09/2009)|
|6.||Ye, Xiaobu: 2 articles (04/2010 - 09/2009)|
|7.||Fisher, Joy: 2 articles (04/2010 - 09/2009)|
|8.||Piantadosi, Steven: 2 articles (04/2010 - 09/2009)|
|9.||Fine, Howard A: 2 articles (04/2010 - 09/2009)|
|10.||Aujla, Paven K: 2 articles (04/2009 - 08/2008)|
06/11/2002 - "A crossover, add-on trial of talampanel in patients with refractory partial seizures."
04/01/2009 - "Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model."
06/11/2002 - "Eighty percent of patients had fewer seizures on talampanel than on placebo. "
06/11/2002 - "Talampanel showed efficacy in reducing seizure frequency (p = 0.001) with a median seizure reduction of 21%. "
06/11/2002 - "The authors report a double-blind, placebo-controlled, crossover study of talampanel in 49 patients with refractory partial seizures. "
04/01/2010 - ": A phase 2 trial was conducted to evaluate the efficacy of talampanel in patients with recurrent malignant glioma as measured by 6-month progression-free survival (PFS6). "
04/01/2010 - ": Talampanel was well-tolerated but had no significant activity as a single agent in unselected recurrent malignant gliomas. "
04/01/2010 - "Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas."
|3.||Brain Ischemia (Cerebral Ischemia)
07/31/2006 - "The focal cerebral ischemia in mice was induced by transient (60 min.) MCA occlusion and 48 h reperfusion and treated with talampanel (6 x 2 mg/kg, i.p.). "
01/15/2006 - "Talampanel improves the functional deficit after transient focal cerebral ischemia in rats. "
12/06/2006 - "In conclusion, the therapeutic time window of neuroprotection by EGIS-8332 and GYKI 53405 was 2 h in permanent and 3 h in transient focal cerebral ischemia in rats. "
07/15/2005 - "The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemia."
09/03/2004 - "Therefore, we evaluated the antiischemic efficacy of [+/-]-7-acetyl-5-[4-aminophenyl]-7,8-dihydro-8-cyano-8-methyl-9H-1,3-dioxolo-[4,5-h]-2,3-benzodiazepine (EGIS-8332) and GYKI 53405, two selective, non-competitive AMPA antagonists in two rat models of focal cerebral ischemia. "
01/01/2003 - "This study examines the single- and multiple-dose pharmacokinetics, safety, and tolerability of talampanel in patients with intractable epilepsy and assesses the potential for pharmacokinetic interaction. "
01/01/2007 - "Talampanel has a broad spectrum of action in animal models of epilepsy and neuroprotection. "
01/01/2003 - "Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy."
04/01/2010 - "Talampanel is an oral AMPA receptor inhibitor with excellent central nervous system penetration and good tolerability in clinical trials for epilepsy and other neurologic disorders. "
06/01/2013 - "Due to an unfavorable kinetic and tolerability profile, talampanel clinical development in the field of epilepsy was discontinued early while perampanel has been recently approved in Europe and the USA as adjunctive therapy for adults with partial seizures with or without secondary generalization. "
01/15/2006 - "The aim of present investigation was to analyze the sensorimotor function after stroke and to test the influence of talampanel (GYKI-53773, LY-300164) by 30-day monitoring in rats. "
07/15/2005 - "Protective actions of talampanel in various stroke models, in rats and mice, suggest a possible therapeutic role of the compound in stroke patients."
07/15/2005 - "The present study is intended to determine whether the non-competitive alpha-amino-3-hydroxy-methyl-4-isoxazolyl-propionic acid (AMPA) receptor antagonist talampanel, known as antiepileptic drug, has neuroprotective effects in stroke models in rodents. "
07/31/2006 - "Talampanel (IVAX) is a non-competitive AMPA-antagonist has a remarkable neuroprotection in different rodent stroke models. "
01/15/2006 - "Our results indicate that modulation of AMPA receptors by talampanel can be a promising therapeutic approach to the treatment of stroke."
|1.||GYKI 53405 (talampanel)
|2.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|3.||AMPA Receptors (AMPA Receptor)
|6.||Kainic Acid Receptors (Kainate Receptor)
|9.||Glutamate Receptors (Glutamate Receptor)
|2.||Drug Therapy (Chemotherapy)